特発性造血障害に関する調査研究

平成29年度~ 現在
研究代表者 三谷絹子 (獨協医科大学)

研究成果achievements

  1. Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T, Maruyama H, Katagiri T, Kishi H, Tajima A, Muraguchi A, Kashiwase K, Nakao S: Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood 129:2908-2916, 2017.
  2. 廣川 誠:赤芽球癆.血液疾患最新の治療2017-2019,小澤敬也,中尾眞二,松村 到(編),南江堂, 東京, 109-112, 2017. 
  3. 廣川 誠:赤芽球癆.1336専門家による私の治療2017-18年度版, 猿田享男,北村惣一郎(編),日本医事新報社,東京, 693-694, 2017.
  4. 廣川 誠:赤芽球癆. 貧血症診断と治療のABC125, 桐戸啓太(編).最新医学社、大阪、99-106, 2017.
  5. 廣川 誠:赤芽球癆:疾患概念・病因・病態.日本臨床, 75(増刊号),431-436, 2017.
  6. 廣川 誠:後天性赤芽球癆の特徴と治療の実際.新薬と臨床, 66, 62-67, 2017.
  7. Nagao T, Hirokawa M: Diagnosis and treatment of macrocytic anemias in adults.  J Gen Fam Med 18:200-204, 2017.
  8. Nishimura J, Kinoshita T, Kanakura Y: Clinical effects of eculizumab in PNH: Poor responders. Paroxysmal nocturnal hemoglobinuria: From bench to bedside. (Kanakura Y, Kinoshita T, Nishimura J, eds.) Springer, Tokyo, 2017, pp297-pp306.
  9. Yamazaki H, Aoki K, Kondo T, Nishikori M, Kitano T, Hishizawa M, Yamashita K, Takaori-Kondo A: Outcome of allogeneic hematopoietic stem cell transplantation in cases of mature T/NK-cell neoplasms: a single-center retrospective analysis. Ann Hematol 96:323-326, 2017.
  10. Sugino N, Kawahara M, Tatsumi G, Kanai A, Matsui H, Yamamoto R, Nagai Y, Fujii S, Shimazu Y, Hishizawa M, Inaba T, Andoh A, Suzuki T, Takaori-Kondo A: A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. Leukemia 31:2303-2314, 2017.
  11. Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kitano T, Kondo T, Hishizawa M, Tomosugi N, Takaori-Kondo A: High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation. Cancer Med 6 :120-128, 2017.
  12. Okuda H, Stanojevic B, Kanai A, Kawamura T, Takahashi S, Matsui H, Takaori-Kondo A, Yokoyama A: Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J Clin Invest 127:1918-1931, 2017.
  13. Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M: A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol 92: 1324-1332, 2017.
  14. Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Zaike Y, Usuki K, Chiba S, Ishikawa T, Arima N, Nogawa M, Ohta A, Miyazaki Y, Mitani K, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A: Validation of the revised International Prognostic scoring system in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. Int J Hematol 106:375-384, 2017.
  15. Jo T, Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita
  16. K, Takaori-Kondo A: Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute. Biol Blood Marrow Transplant 23:2159-2165, 2017.
  17. Chonabayashi K, Yoshida Y, Takaori-Kondo A: Reprogramming technology reveals genetic and functional diversity of subclones in myelodysplastic syndromes. Rinsho Ketsueki 58:787-791, 2017.
  18. Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A: Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 58 :1840-1848, 2017.
  19. Li L, Sheng Y, Li W, Hu C, Mittal N, Tohyama K, Seba A, Zhao Y, Ozer H, Zhu T, Qian Z: β-Catenin is a candidate therapeutic target for myeloid neoplasms with del(5q).  Cancer Res 77:4116-4126, 2017.
  20. Oben KZ, Alhakeem SS , McKenna MK, Brandon JA, Mani R, Noothi SK, Jinpeng L, Akunuru S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills Jr HF, St. Clair DK, Geiger H, Muthusamy N, Tohyama K, Gupta RC, Bondada S: Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by withaferin-A. Oncotarget 8 :77436-77452, 2017.
  21. 松田晃:骨髄異形成症候群の形態診断.臨床血液 58:336-346, 2017.
  22. Minami M, Arita T, Iwasaki H, Muta T, Aoki T, Aoki K, Yamasaki S, Matsushima T, Kato K, Takenaka K, Tanimoto K, Kamimura T, Ogawa R, Akashi K, Miyamoto T: Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol 177:578-587, 2017.
  23. Miyawaki K, Iwasaki H, Jiromaru T, Kusumoto H, Yurino A, Sugio T, Uehara Y, Odawara J, Daitoku S, Kunisaki Y, Mori Y, Arinobu Y, Tsuzuki H, Kikushige Y, Iino T, Kato K, Takenaka K, Miyamoto T, Maeda T, Akashi K: Identification of unipotent megakaryocyte progenitors in human hematopoiesis. Blood 129:3332-3343, 2017.
  24. Yuda J, Miyamoto T, Odawara J, Ohkawa Y, Semba Y, Hayashi M, Miyamura K, Tanimoto M, Yamamoto K, Taniwaki M, Akashi K: Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. Cancer Sci 108: 2204-2212, 2017.
  25. Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Kimura SI, Kikuchi M, Yamazaki R, Kako S, Kanda Y: Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol 105:578-586, 2017.
  26. Kako S, Kanda Y, Kato J, Yamamoto W, Kato S, Onizuka M, Yokota A, Tatara R, Yokoyama H, Hagihara M, Usuki K, Gotoh M, Watanabe R, Kawai N, Saitoh T, Kanamori H, Takahashi S, Okamoto S: The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. Hematol Oncol 35,341-349, 2017.
  27. Muramatsu H, Okuno Y, Yoshida K, Shiraishi Y, Doisaki S, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, Chiba K, Tanaka H, Hama A, Sanada M, Takahashi Y, Kanno H, Yamaguchi H, Ohga S, Manabe A, Harigae H, Kunishima S, Ishii E, Kobayashi M, Koike K, Watanabe K, Ito E, Takata M, Yabe M, Ogawa S, Miyano S, Kojima S: Clinical utility of next-generation sequencing for bone marrow failure syndrome. Genet Med 19:796-802, 2017.
  28. Kanamitsu K, Shimada A, Nishiuchi R, Shigemura T, Nakazawa Y, Koike K, Kodama Y, Shinkoda Y, Kawano Y, Yasui K, Sasaki K, Kajiwara R, Tsukahara H, Manabe A: Pediatric intestinal Behcet disease complicated by myeloid malignancies. Int J Hematol 105:377-382, 2017.
  29. Hirabayashi S, Seki M, Hasegawa D, Kato M, Hyakuna N, Shuo T, Kimura S, Yoshida K, Kataoka K, Fujii Y, Shiraishi Y, Chiba K, Tanaka H, Kiyokawa N, Miyano S, Ogawa S, Takita J, Manabe A: Constitutional abnormalities of IDFH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. Pediatr Blood Cancer, 2017.
  30. Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, Shima M: Pediatric Thromboembolism: A National Survey in Japan. Int J Hematol 105:52-58, 2017.
  31. Hasegawa D, Manabe A: Myelodysplastic syndrome and JMML. In: Ishii E, editor. Hematological disorders in children - Pathogenesis and treatment, p87-108, 2017, Springer (Berlin).
  32. 平林真介,真部淳:家族性造血器腫瘍. 臨床血液 58:1878-1883, 2017.
  33. Maruyama K, Aotsuka N, Kumano Y, Sato N, Kawashima N, Onda Y, Maruyama H, Katagiri T, Zaimoku Y, Nakagawa N, Hosomichi K, Ogawa S, Nakao S: Immune-Mediated Hematopoietic Failure after Allogeneic Hematopoietic Stem Cell Transplantation: A Common Cause of Late Graft Failure in Patients with Complete Donor Chimerism. Biol Blood Marrow Transplant 24:43-49, 2018.
  34. Kawakami T, Sekiguchi N, Kobayashi J, Imi T, Matsuda K, Yamane T, Nishina S, Senoo Y, Sakai H, Ito T, Koizumi T, Hirokawa M, Nakao S, Nakazawa H, Ishida F: Frequent STAT3 mutations in CD8(+) T cells from patients with pure red cell aplasia. Blood Adv 2:2704-2712, 2018.
  35. Imi T, Katagiri T, Hosomichi K, Zaimoku Y, Hoang Nguyen V, Nakagawa N, Tajima A, Yoshizato T, Ogawa S, Nakao S: Sustained clonal hematopoiesis by HLA- lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Adv 2:1000-1012, 2018.
  36. Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S: Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria- type cells specific to patients with bone marrow failure. Ann Hematol 97: 2289-2297, 2018.
  37. Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Takamatsu H, Ozawa T, Maruyama H, Hassanein HA, Khalifa ANA, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S: Hematopoiesis by iPSC- derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. Blood Adv 2:390-400, 2018.
  38. 廣川 誠:赤芽球癆.血液細胞アトラス第6版,通山 薫,張替秀郎(編),文光堂, 東京, 207-210, 2018. 
  39. 廣川 誠:再生不良性貧血.今日の治療指針2018年版,福井次矢,高木 誠,小室一成(編).医学書院、東京、647-649, 2018.
  40. 藤島直仁,廣川 誠:赤芽球癆の診療・最新の動向.血液内科,76, 15-19, 2018.
  41. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura JI, Kanakura Y, Ninomiya H: Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobi- nuria in Japan. Int J Hematol 107:656-665, 2018.
  42. 松田晃, 張替秀郎, 通山薫:骨髄異形成症候群, 血液細胞アトラス第6版(通山薫, 張替秀郎 編集), 文光堂(東京),pp271-282, 2018.
  43. Matsuda A, Kawabata H, Tohyama K, Maeda T, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Usuki K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Ohta A, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Mitani K, Takaori-Kondo A: Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leuk Res 74:137-143, 2018.
  44. Masuda K, Shiga S, Kawabata H, Takaori-Kondo A, Ichiyama S, Kamikubo Y: PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients. Int J Hematol 108: 30-38, 2018.
  45. Tohyama K: Present status and perspective of laboratory hematology in Japan: On the standardization of blood cell morphology including myelodysplasia: On behalf of the Japanese Society for Laboratory Hematology.  Int J Lab Hematol 40(Suppl 1): 120-125, 2018.
  46. Nakahara T, Suemori S, Tsujioka T, Kataoka M, Kataoka H, Shibakura M, Tohyama K: Utility of a fluorescence microscopy imaging system for analyzing the DNA ploidy of pathological megakaryocytes including 5q- syndrome.  Acta Medica Okayama 72: 249-256, 2018.
  47. Kida J, Tsujioka T, Suemori S, Okamoto S, Sakakibara K, Takahata T, Yamauchi T, Kitanaka A, Tohyama Y, Tohyama K: An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS.  Leukemia 32:1846-1850, 2018.
  48. Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, Du J, Wang H, Wu X, Zhang L, Yu X, Lin A, McDonald T, Zhao D, Wu H, Hua WK, Zhang B, Feng L, Tohyama K, Bhatia R, Oberdoerffer P, Chung YJ, Aplan PD, Boultwood J, Pellagatti A, Khaled S, Kortylewski M, Pichiorri F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L: SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. Cell Stem Cell 23:355-369, 2018.
  49. Morita H, Matsuoka A, Kida JI, Tabata H, Tohyama K, Tohyama Y: KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line. Int J Hematol 108: 607-614, 2018.
  50. Horai M, Satoh S, Matsuo M, Iwanaga M, Horio K, Jo T, Takasaki Y, Kawaguchi Y, Tsushima H, Yoshida S, Taguchi M, Itonaga H, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Moriuchi Y, Haase D, Yoshiura KI, Miyazaki Y: Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki.  Br J Haematol 180:381-390, 2018.
  51. Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL: Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leuk Res 73:51-57, 2018.
  52. Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, Sakura T, Ohashi K, Kurokawa M, Ozawa Y, Matsuoka KI, Nakamura Y, Kimura F, Iwato K, Nawa Y, Hirokawa M, Kato K, Ichinohe T, Atsuta Y, Miyazaki Y: Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan. Biol Blood Marrow Transplant 24:840-848, 2018.
  53. Mizuno S, Iino T, Ozawa H, Arinobu Y, Chong Y, Akashi K: Notch1 expression is regulated at the post-transcriptional level by the 3' untranslated region in hematopoietic stem cell development. Int J Hematol 107:311-319, 2018.
  54. Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K: Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Curr Med Res Opin 34: 531-537, 2018.
  55. Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N: Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. Int J Hematol 107:92-97, 2018.
  56. Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg VAC, Cole MA, Macias-Trevino C, Ishikawa Y, Yao Q, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T: Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell 33:386-400, 2018.
  57. Takenaka K, Shimoda K, Akashi K: Recent advances in the diagnosis and management of primary myelofibrosis. Korean J Intern Med 33:679-690, 2018.
  58. Mashima K, Ikeda T, Toda Y, Ito S, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Fujiwara S, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y: Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. Leuk Lymphoma 6:1-8, 2018.
  59. Hamada M, Doisaki S, Okuno Y, Muramatsu H, Hama A, Kawashima N, Narita A, Nishio N, Yoshida K, Kanno H, Manabe A, Taga T, Takahashi Y, Miyano S, Ogawa S, Kojima S: Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. Int J Hematol 108:306-311, 2018.
  60. 平林真介, 鈴木美慧, 真部淳:TP53変異と造血器腫瘍. 臨床血液 59:2468-2474, 2018.
  61. Kobayashi M, Tojo A: Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment. Cancer Sci 109: 3707-13, 2018.
  62. Elbadry MI, Espinoza JL, Nakao S: Disease modeling of bone marrow failure syndromes using iPSC-derived hemato- poietic stem progenitor cells. Exp Hematol 71:32-42, 2019.
  63. Ishiyama K, Aoki J, Itonaga H, Uchida N, Takahashi S, Ohno Y, Matsuhashi Y, Sakura T, Onizuka M, Miyakoshi S, Takanashi M, Fukuda T, Atsuta Y, Nakao S, Miyazaki Y: Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. Blood Cancer J 9:31, 2019.
  64. Hosokawa K, Mizumaki H, Elbadry MI, Saito C, Espinoza JL, Thi Thanh Dao A, Katagiri T, Harashima A, Kikuchi A, Kanai A, Matsui H, Inaba T, Taniwaki M, Yamamoto Y, Nakao S: Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia. Leukemia 33:2732-2766, 2019.
  65. Hino T, Imi T, Hangaishi A, Kamoda Y, Iizuka H, Hirao M, Kida M, Tojo A, Nakao S, Usuki K: Escape hematopoiesis by donor-derived 6pLOH(+) hematopoietic stem cells in a marrow transplant recipient with late graft failure. Bone Marrow Transplant 54:1129-1132, 2019.
  66. Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S: Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia. Haematologica 104:e447-e450, 2019.
  67. 廣川 誠:赤芽球癆.血液専門医テキスト第3版,日本血液学会(編),南江堂, 東京, 211-213, 2019. 
  68. 廣川 誠:赤芽球癆.今日の治療指2019年版,福井次矢,高木 誠,小室一成(編).医学書院、東京、666-667, 2019.
  69. 廣川 誠:赤芽球癆.未来型血液治療学,小松則夫(編),中外医学社,東京,76, 21-31, 2019.
  70. Sakurai M, Jang JH, Chou WC, Kim JS, Wilson A, Nishimura JI, Chiou TJ, Kanakura Y, Lee JW, Okamoto S: Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 110:411-418, 2019.
  71. Höchsmann B, Murakami Y, Osato M, Knaus A, Kawamoto M, Inoue N, Hirata T, Murata S, Anliker M, Eggerman T, Jäger M, Floettmann R, Höllein A, Murase S, Ueda Y, Nishimura JI, Kanakura Y, Kohara N, Schrezenmeier H, Krawitz PM, Kinoshita T: Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. J Clin Invest 129:5123-5136, 2019.
  72. Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes: Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol 110:533-542, 2019.
  73. Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y, Tomiyama Y, Usuki K, Imajo K, Miyamura K, Sasaki O, Fanghong Z, Hattori T, Tajima T, Matsuda A, Nakao S: Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol 110:187-196, 2019.
  74. Murakami Y, Kimura Y, Kawahara A, Mitsuyasu S, Miyake H, Tohyama K, Endo Y, Yoshida N, Imamura Y, Watari K, Ono M, Okamura T, Kuwano M: The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. Oncotarget 10:2270-2281, 2019.
  75. 松田晃:MDSの診断 細胞形態学的所見.日本臨床77: 1467-1482, 2019.
  76. Hashimoto M, Itonaga H, Nannya Y, Taniguchi H, Fukuda Y, Furumoto T, Fujioka M, Kasai S, Taguchi M, Taniguchi H, Sato S, Sawayama Y, Atogami S, Iwasaki K, Hata T, Soda H, Moriuchi Y, Nakata K, Ogawa S, Miyazaki Y: Secondary Pulmonary Alveolar Proteinosis Following Treatment With Azacitidine for Myelodysplastic Syndrome. Intern Med, 2019.
  77. Ishida T, Ohashi K, Okina C, Ohashi S, Okina S, Miyazaki K, Suzuki T: Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors. Int J Hematol 110:237-243, 2019.
  78. Aoki T, Kamimura T, Yoshida S, Mori Y, Kadowaki M, Kohno K, Ishihara D, Urata S, Sugio T, Kamezaki K, Kato K, Ito Y, Eto T, Akashi K, Miyamoto T: Safety and seropositivity after live attenuated vaccine in adult patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 25:1576-158, 2019.
  79. Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T, Ohta T, Takase K, Henzan H, Muta T, Iwasaki H, Ogawa R, Eto T, Akashi K, Miyamoto T: Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation. Ann Hematol 98:2579-2591, 2019.
  80. Mashima K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Ishihara Y, Ashizawa M, Yamamoto C, Fujiwara SI, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y: Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. Ann Hematol 98:1127-1133, 2019.
  81. Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K: Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol 37:85-95, 2019.
  82. Mori T, Onishi Y, Ozawa Y, Kato C, Kai T, Kanda Y, Kurokawa M, Tanaka M, Ashida T, Sawayama Y, Fukuda T, Ichinohe T, Atsuta Y, Yamazaki H: Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. Int J Hematol 109:711-717, 2019.
  83. Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K: Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol 37:85-95, 2019.
  84. Mashima K, Ikeda T, Toda Y, Ito S, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Fujiwara S, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y: Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. Leuk Lymphoma 60:703-710, 2019.
  85. Takaoka K, Kawazu M, Koya J, Yoshimi A, Masamoto Y, Maki H, Toya T, Kobayashi T, Nannya Y, Arai S, Ueno H, Suzuki K, Harada H, Manabe A, Hayashi Y, Mano H, Kurokawa M: A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. Leukemia 33:1773-1782, 2019.
  86. 平林真介,真部淳:小児がんと家族性腫瘍.家族性腫瘍 19:28-31, 2019.
  87. 巽浩一郎, 井上義一:ランゲルハンス細胞組織球症(LCH). 呼吸器内科35:142-149, 2019.
  88. Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, Young LR, McCormack FX, Inoue Y: Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One 28: e0212776, 2019.
  89. Schols S, Nunn MA, Mackie I, Weston-Davies W, Nishimura JI, Kanakura Y, Blijlevens N, Muus P, Langemeijer S: Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan). Br J Haematol 188:334-337, 2020.
  90. Takaoka K, Koya J, Yoshimi A, Toya T, Kobayashi T, Nannya Y, Nakazaki K, Arai S, Ueno H, Usuki K, Yamashita T, Imanishi D, Sato S, Suzuki K, Harada H, Manabe A, Hayashi Y, Miyazaki Y, Kurokawa M: Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. Leukemia Lymphoma, 2020.
  91. Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT): Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol 95:251-257, 2020.
  92. Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, Maeda T, Kato J, Ishiyama K, Matsuoka KI, Miyamoto T, Iida H, Ikegame K, Fukuda T, Ichinohe T, Atsuta Y, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation: Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transplant 26:445-450, 2020.
  93. Liu H, Osterburg AR, Flury J, Swank Z, McGraw DW, Gupta N, Wikenheiser-Brokamp KA, Kumar A, Tazi A, Inoue Y, Hirose M, McCormack FX, Borchers MT: MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 27;5(4). pii: 132048, 2020.
  94. 東條有伸:ランゲルハンス細胞組織球症(LCH)(成人)「専門家による私の治療」. 日本医事新報 No.5002(3月1週号)pp39〜pp40、2020.
  95. 真部淳:小児における生殖細胞系列の遺伝子検索の問題点. 臨床血液 61:682-686, 2020.

研究事務局

獨協医科大学 内科学(血液・腫瘍)
〒321-0293 栃木県下都賀郡壬生町北小林880
Tel: 0282-86-1111 内線2740
研究代表者 三谷絹子
事務局担当 今井陽一